Gemstone utilizes exclusively-licensed core technology that was developed at Johns Hopkins University. The IP portfolio comprises a unique mix of innovative products and techniques. Our technology boasts a wide-range of regenerative medicine applications, including wound healing scaffolds and topical therapeutics.
Gemstone’s technology is published in a variety of high-impact journals. Our science is subjected to rigorous peer-review to ensure scientific integrity and verifiable results.
This mini-review provides a brief overview of chronic wound healing and current skin substitute treatment strategies while focusing on recent engineering approaches that regenerate skin using synthetic, biopolymeric scaffolds.
New study results show 3rd degree wounds treated with our product achieved complete re-epithelialization and nerve ingrowth. The regenerated skin demonstrated characteristics of uninjured skin. This affirms the superior wound healing performance of our biosynthetic scaffold technology.
A bicellular vascular population, capable of maturing into ECs and pericytes, was derived from human pluripotent stem cells (hPSCs). These EVCs were able to self-organize and form microvascular networks in an engineered matrix, which survives implantation, integrates with the host vasculature, and establishes blood flow.
A biosynthetic scaffold containing no additional growth factors, cytokines, or cells was developed that promotes neovascularization and skin regeneration in third-degree burn wounds in mice. Dermal regeneration with complete skin appendages was observed after 3 weeks. After 5 weeks, new hair growth and normal epidermal morphology and thickness were observed.
Synthetic, tunable hyaluronic acid (HA) hydrogels were developed that enabled human endothelial colony-forming cells (ECFCs) to form efficient vascular networks in vivo. HA hydrogels containing ECFCs anastomosed with the host’s circulation and supported blood flow in the hydrogel after transplantation. regeneration.